Warning: The NCBI web site requires JavaScript to function. more...
Interleukin-6: a new therapeutic target.
Smolen JS, Maini RN.
Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. Review. Erratum in: Arthritis Res Ther. 2006;8(6):407.
Related citations
Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E.
Curr Rheumatol Rep. 2008 Oct;10(5):413-7.
Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD.
Expert Opin Biol Ther. 2009 Dec;9(12):1463-75. Review.
Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H, Nishimoto N.
Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):373-81. Review.
Targeted therapy in rheumatoid arthritis.
Köller MD.
Wien Med Wochenschr. 2006 Jan;156(1-2):53-60. Review.
[New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL.
Ter Arkh. 2010;82(5):64-71. Review. Russian.
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.
Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N.
Mod Rheumatol. 2009;19(4):351-7. Epub 2009 Jul 10.
Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E.
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):697-700. Epub 2011 Sep 1.
Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT.
Drugs. 2009 Oct 22;69(15):2035-43. doi: 10.2165/11318290-000000000-00000.
Interleukin-6 in rheumatoid arthritis.
Nishimoto N.
Curr Opin Rheumatol. 2006 May;18(3):277-81. Review.
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J.
Ann Rheum Dis. 2008 Nov;67(11):1516-23. Epub 2008 Jul 14. Erratum in: Ann Rheum Dis. 2009 Feb;68(2):296.
Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y.
Biol Pharm Bull. 2007 Nov;30(11):2001-6. Review.
[Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J.
Reumatizam. 2008;55(2):70-2. Review. Croatian.
Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
Voll RE, Kalden JR.
Ann N Y Acad Sci. 2005 Jun;1051:799-810. Review.
New therapies for rheumatoid arthritis.
Goldblatt F, Isenberg DA.
Clin Exp Immunol. 2005 May;140(2):195-204. Review.
Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects.
Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G.
Clin Rev Allergy Immunol. 2005 Jun;28(3):239-48. Review.
Tocilizumab: is there life beyond anti-TNF blockade?
Alves JD, Marinho A, Serra MJ.
Int J Clin Pract. 2011 Apr;65(4):508-13. doi: 10.1111/j.1742-1241.2010.02612.x. Epub 2011 Jan 28. Review.
[Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nihon Rinsho. 2007 Jul;65(7):1218-25. Review. Japanese.
Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
Kavanaugh A.
Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S16-20. Review.
Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R, Ruderman EM.
Bull NYU Hosp Jt Dis. 2010;68(3):211-7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on